Danish manufacturer Novo Nordisk announced it is seeking a provisional injunction from a US court to immediately block advertisements for obesity and diabetes drugs by American company Eli Lilly. The lawsuit involves popular medications like Wegovy, Ozempic, Mounjaro, and Zepbound.

Eli Lilly announced that its drugs Foundayo and Zepbound will be accessible to Medicare Part D beneficiaries starting July 1.

A new generation of weight-loss therapies is under development, promising to offer improved efficacy and convenience compared to existing GLP-1 drugs like Zepbound and Wegovy.

Pharmaceutical company Eli Lilly announced strong financial results for the first quarter of 2026, with significant growth attributed to the performance of its key drugs, Mounjaro and Zepbound.

Eli Lilly is reportedly not just replacing its drug Zepbound but is actively expanding its presence to build a dominant position in the broader obesity treatment market.

Major US weight-loss drug manufacturers are reducing prices for medicines like Zepbound as they compete to attract customers and make treatments more affordable.

If middle-class Americans lose their jobs to AI, that could mean fewer cash sales of weight-loss drugs like Zepbound.

Amazon Pharmacy is expanding its range of GLP-1 medications by adding the Zepbound KwikPen to its offerings.

Novo's stumbles burnish Lilly's widening lead in weight-loss drugs  Reuters

Novo Nordisk's shares dropped significantly after its new obesity drug did not demonstrate superior efficacy compared to Zepbound.

Novo Nordisk's shares experienced a significant drop after its obesity drug did not demonstrate superior efficacy compared to Zepbound in clinical trials.

Lilly announced that a regimen including its drug Zepbound demonstrated success in a clinical trial for treating psoriasis.

A new Medicare GLP-1 Bridge program, effective July 1, will reduce the cost of weight-loss drugs like Wegovy and Zepbound to $50 a month for eligible seniors.

NBA legend Shaquille O’Neal has disclosed he is taking a GLP-1 medication, such as Zepbound, linking his decision to a long-standing health condition and joining other high-profile figures using these drugs.

Eli Lilly and Company’s (LLY) drugs Foundayo and Zepbound are set to be covered for millions of Americans, expanding access to these treatments.

CVS Health has reinstated coverage for Eli Lilly's weight-loss drug Zepbound.

Shares of Eli Lilly & Co. fell in premarket trading after new industry prescription data for its blockbuster obesity drug Zepbound disappointed Wall Street investors.

An overview of the rapidly growing GLP-1 market details the costs of popular weight-loss medications like Wegovy, Zepbound, and Foundayo, and offers advice on choosing the best option.

Eli Lilly has introduced its Zepbound KwikPen for weight management, making it available through the telehealth platform Ro.

This week's notable healthcare headlines focus on key developments concerning pharmaceutical companies such as Eli Lilly, which is expanding Zepbound access, along with Novo Nordisk and Novartis.

American restaurant chains are reconsidering both menus and portion sizes after the use of so-called GLP-1 drugs, such as Ozempic, Wegovy, and Zepbound, has increased significantly.

The Danish drugmaker released late-stage data showing that the upcoming injection CagriSema failed to match the weight loss of Eli Lilly’s Zepbound.

Eli Lilly’s Zepbound Gets FDA OK for Multi-Dose Pen  The Wall Street Journal

Novo Nordisk's shares experienced a significant drop after its new obesity drug failed to outperform Eli Lilly's Zepbound in clinical trials.

Research suggests a new blood test may be able to predict the effectiveness of the medication Zepbound.

The popularity of the weight-loss drug Zepbound has inadvertently generated a $1.3 billion financial boost for various religious organizations, according to a new report.

Shaquille O'Neal has revealed he is taking a GLP-1 medication, Zepbound, not for weight loss but to treat obstructive sleep apnea, partnering with Eli Lilly to raise awareness.

CVS will soon cover Eli Lilly's GLP-1 medications, including Foundayo and Zepbound, potentially providing access to these drugs for millions more Americans.

Eli Lilly announced clinical trial results for retatrutide, its next gen obesity drug. The drug helped study participants lose 70 lbs over 80 weeks, making it more powerful than Zepbound and Wegovy.

Millions of patients have lost coverage for popular obesity drugs like Zepbound and Wegovy over the past year due to new restrictions, forcing many to seek alternative treatments.

Novo Nordisk has launched the high-dose version of its GLP-1 injection, Wegovy, at a price point $50 lower than Eli Lilly's competing drug, Zepbound. This strategic pricing aims to position Wegovy competitively in the market.

Insurance companies are increasingly cutting off coverage for popular weight-loss medications like Zepbound, leaving patients who have seen significant results without access to their prescriptions.

Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill, orforglipron.

Novo has been downgraded by J.P. Morgan, as its next-generation obesity drug is reportedly trailing behind Lilly’s Zepbound in market performance.

Novo Nordisk Shares Plunge After Obesity Drug Fails to Beat Zepbound  WSJ

Novo Nordisk's shares experienced a significant drop after its obesity drug did not demonstrate superior efficacy compared to Zepbound in clinical trials.

Eli Lilly has announced a landmark trial demonstrating a major breakthrough with its Taltz-Zepbound drug combination for treating both psoriasis and obesity.